Want to see JP:4569 full AI Analyst Report?
4569 Stock Chart & Stats
¥1537.00
-¥23.00(-1.53%)
At close: 4:00 PM EST
¥1537.00
-¥23.00(-1.53%)
Day’s Range― - ―
52-Week Range¥1,067.00 - ¥1,725.00
Previous CloseN/A
Volume61.80K
Average Volume (3M)127.03K
Market Cap
¥62.17B
Enterprise Value¥75.23B
Total Cash (Recent Filing)¥15.08B
Total Debt (Recent Filing)¥23.79B
Price to Earnings (P/E)19.5
Beta0.48
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.36%
Share Statistics
EPS (TTM)60.01
Shares Outstanding59,945,640
10 Day Avg. Volume147,840
30 Day Avg. Volume127,030
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)0.66
Price to Sales (P/S)0.75
P/FCF Ratio37.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27
Revenue Forecast (FY)¥124.60B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and steadily growing equity provide durable financial flexibility. Conservatively financed balance sheet supports R&D funding, manufacturing investments or targeted M&A without immediate refinancing risk, improving resilience against sector pricing or reimbursement shifts over the next several quarters.
Recent Cash Generation ReboundImproved operating cash flow and a return to positive free cash flow demonstrate the company's capacity to convert earnings to cash when operating conditions stabilize. This supports internal funding for launches, ongoing clinical work and shareholder distributions without immediate reliance on external capital.
Focused Therapeutic FranchiseA clear focus on respiratory, infectious and allergy therapeutics builds deep clinical expertise and established customer relationships with Japanese medical institutions. This specialization supports steady demand, predictable commercialization pathways and lifecycle management under Japan's reimbursement framework over the medium term.
Bears Say
Margin CompressionSignificant decline in gross and net margins signals structural pressure from cost increases, pricing mix shifts or product lifecycle decline. Persistently lower margins reduce reinvestment capacity and erode returns to shareholders, making long-term profitability recovery more challenging without new high-margin products.
Recent Revenue DeclineA year-over-year revenue drop interrupts prior multi-year growth and may reflect weaker product demand or competitive pressures. Sustaining top-line growth is critical for leveraging fixed R&D and manufacturing costs; continued declines would impair scale benefits and prolong margin recovery over the next several quarters.
Volatile Free Cash FlowA swingy free cash flow profile reduces predictability of internal funding for development, capex and dividends. Even with low leverage, inconsistent cash conversion increases the risk of external financing needs during downturns and complicates multi-year planning for pipelines or commercial expansion.
KYORIN Pharmaceutical Co.,Ltd. News
4569 FAQ
What was KYORIN Pharmaceutical Co.,Ltd.’s price range in the past 12 months?
KYORIN Pharmaceutical Co.,Ltd. lowest stock price was ¥1067.00 and its highest was ¥1725.00 in the past 12 months.
What is KYORIN Pharmaceutical Co.,Ltd.’s market cap?
KYORIN Pharmaceutical Co.,Ltd.’s market cap is ¥62.17B.
When is KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date?
KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date is Jul 30, 2026 which is in 13 days.
How were KYORIN Pharmaceutical Co.,Ltd.’s earnings last quarter?
KYORIN Pharmaceutical Co.,Ltd. released its earnings results on May 12, 2026. The company reported -¥11.68 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.68.
Is KYORIN Pharmaceutical Co.,Ltd. overvalued?
According to Wall Street analysts KYORIN Pharmaceutical Co.,Ltd.’s price is currently Overvalued.
Does KYORIN Pharmaceutical Co.,Ltd. pay dividends?
KYORIN Pharmaceutical Co.,Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 3.36%. See more information on KYORIN Pharmaceutical Co.,Ltd. dividends here
What is KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate?
KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KYORIN Pharmaceutical Co.,Ltd. have?
KYORIN Pharmaceutical Co.,Ltd. has 59,945,640 shares outstanding.
What happened to KYORIN Pharmaceutical Co.,Ltd.’s price movement after its last earnings report?
KYORIN Pharmaceutical Co.,Ltd. reported an EPS of -¥11.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.259%.
Which hedge fund is a major shareholder of KYORIN Pharmaceutical Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:4569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KYORIN Pharmaceutical Co.,Ltd.
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―